Valuation: Tectonic Therapeutic, Inc.

Market Cap 412M 368M 340M 308M 577M 39.14B 586M 4.09B 1.62B 20.49B 1.55B 1.51B 64.65B P/E 2026 *
-4.08x
P/E 2027 * -3.97x
Enterprise Value 87.36M 78M 72M 65.33M 122M 8.29B 124M 867M 344M 4.34B 328M 321M 13.7B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
62.4%
Yield 2026 *
-
Yield 2027 * -
1 day-4.84%
1 week-5.77%
Current month-13.83%
1 month-24.26%
3 months-36.47%
6 months-29.58%
Current year-3.79%
1 week 19.83
Extreme 19.8301
22.44
1 month 19.83
Extreme 19.8301
24.86
Current year 16.77
Extreme 16.77
39.53
1 year 15.52
Extreme 15.52
39.53
3 years 13.7
Extreme 13.7
61.07
5 years 13.7
Extreme 13.7
61.07
10 years 13.7
Extreme 13.7
61.07
Date Insider Type Main position Quantity % Market Cap. Importance
30/09/26 Sell

Chief Technology Officer

-536 0.0027%
25/09/26 Tax

Chief Technology Officer

-525 0.0027%
25/09/26 Tax

Chief Executive Officer

-1,545 0.0079%
Change 5-day change 1-year change 3-year change Capi.($)
-4.84%-5.77%+13.39% - 412M
+2.41%-6.33%+43.43%+71.02% 63.29B
-0.15%+3.11%+10.29%+72.56% 54.89B
+0.57%+4.64%+12.82%+89.79% 53.28B
+0.37%+3.07%+28.23%+51.53% 45.81B
-1.21%+0.95%+20.44%+128.58% 43.46B
-0.37%-1.20%+252.94%+568.54% 40.23B
+0.05%+6.75%+14.48%+56.75% 33.45B
+1.19%-5.84%+27.86%-0.65% 23.7B
-0.38%+4.55%+37.71%+28.10% 23.76B
Average -0.24%+0.19%+46.16%+118.47% 38.23B
Weighted average by Cap. +0.37%+0.55%+48.13%+122.11%

Financials

2026 *2027 *
Net sales - -
Net income -103M -91.63M -84.58M -76.76M -144M -9.74B -146M -1.02B -404M -5.1B -385M -377M -16.1B -135M -120M -111M -101M -188M -12.78B -191M -1.34B -529M -6.69B -505M -494M -21.11B
Net Debt -325M -290M -268M -243M -455M -30.85B -462M -3.23B -1.28B -16.15B -1.22B -1.19B -50.95B -321M -287M -265M -240M -450M -30.49B -457M -3.19B -1.26B -15.96B -1.21B -1.18B -50.37B
Projected Income Statement - Annual - Tectonic Therapeutic, Inc.
Logo Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Its product candidates are TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. Its second development candidate, TX2100, is a VHH-Fc fusion antagonist antibody that binds to the APJ receptor (APLNR), also known as the apelin receptor. Its APJ is a differentiated approach for the treatment of hereditary hemorrhagic telangiectasia (HHT) and is a selective anti-angiogenic target that is primarily expressed in endothelial cells.
Employees
60
Date Price Change Volume
23/10/26 $20.07 -4.84% 144,968
22/10/26 $21.09 -3.43% 251,375
21/10/26 $21.84 +0.07% 152,828
20/10/26 $21.83 +3.19% 144,520
19/10/26 $21.15 +2.42% 202,965
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Tectonic Therapeutic, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
21.09USD
Average target price
71.00USD
Spread / Average Target
+236.65%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Tectonic Therapeutic, Inc.
  1. Stock Market
  2. Stocks
  3. TECX Stock